Suppr超能文献

乳腺癌隐性遗传表型能否定义?

Can a phenotype for recessive inheritance in breast cancer be defined?

机构信息

Department of Oncology, Clinical Sciences, Lund University Hospital, Lund University, Barngatan 2b, 221 85 Lund, Sweden.

出版信息

Fam Cancer. 2010 Dec;9(4):525-30. doi: 10.1007/s10689-010-9355-4.

Abstract

While a dominant inheritance of breast cancer (vertical inheritance) is well known, less is known about a possible recessive inheritance (horizontal inheritance). In a clinical series of 1676 breast cancer patient's family history was scored as vertical (grandmother-aunt-mother-sister-daughter) or horizontal (sister-sister) and related to histopathological tumor type, presence of germline mutations, bilaterality, multifocality, screening, parity, hormone replacement therapy (HRT) use and age at diagnosis. Prognosis was estimated by also adding tumor size, lymph node status, distant metastases and hormone receptor status at diagnosis into a Cox proportional hazard model. Excluding mutations carriers, a horizontal family history (5% of all cases) was significantly associated with tubular tumor type [OR = 3.87(1.44-10.41)]. A vertical family history (23% of all cases) was significantly related to tumor multifocality [OR = 2.30(1.51-3.50)], tumor bilaterality [OR = 2.08(1.44-3.00)] and screening detection [OR = 1.50(1.10-2.05)]. No significant difference in survival could be seen between patients with none, horizontal or vertical family history. However, germline mutation carriers (BRCA1/2, TP53 or CDKN2A, present in 0.95% of the cases) had a significantly worse survival. Screening detected cases, HRT ever users and patients with estrogen receptor positive tumors had a significantly better survival adjusting for age at diagnosis, tumor size, lymph node status and presence of distant metastases at diagnosis. Factors associated with a horizontal family history were found, defining a possible phenotype for a recessive inheritance: tubular breast cancer.

摘要

虽然乳腺癌的显性遗传(垂直遗传)是众所周知的,但关于可能的隐性遗传(水平遗传)知之甚少。在一个 1676 例乳腺癌患者的临床系列中,家族史被评分分为垂直(祖母-阿姨-母亲-姐妹-女儿)或水平(姐妹-姐妹),并与组织病理学肿瘤类型、种系突变、双侧性、多灶性、筛查、生育史、激素替代疗法(HRT)使用和诊断时的年龄有关。通过将肿瘤大小、淋巴结状态、远处转移和诊断时的激素受体状态也纳入 Cox 比例风险模型,来估计预后。排除突变携带者后,水平家族史(所有病例的 5%)与管状肿瘤类型显著相关[OR=3.87(1.44-10.41)]。垂直家族史(所有病例的 23%)与肿瘤多灶性[OR=2.30(1.51-3.50)]、肿瘤双侧性[OR=2.08(1.44-3.00)]和筛查检出[OR=1.50(1.10-2.05)]显著相关。无家族史、水平家族史或垂直家族史的患者之间的生存差异无统计学意义。然而,种系突变携带者(BRCA1/2、TP53 或 CDKN2A,存在于 0.95%的病例中)的生存明显较差。调整诊断时的年龄、肿瘤大小、淋巴结状态和远处转移的存在,筛查检出的病例、曾使用 HRT 的病例和雌激素受体阳性肿瘤的患者的生存明显更好。发现了与水平家族史相关的因素,定义了一种可能的隐性遗传表型:管状乳腺癌。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验